Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors
about
Structure and functionality in flavivirus NS-proteins: perspectives for drug designChaperones in hepatitis C virus infectionCuring a viral infection by targeting the host: the example of cyclophilin inhibitorsThe Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus ReplicationMK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A ProteaseA new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutantsAn integrated transcriptomic and meta-analysis of hepatoma cells reveals factors that influence susceptibility to HCV infectionDEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5ARanking high affinity ligands of low solubility by NMR spectroscopyFragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activitiesA derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitroBarriers of hepatitis C virus interspecies transmissionProfile of alisporivir and its potential in the treatment of hepatitis C.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitorsNew strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agentsDomain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.Antiviral drugs against hepatitis C virus.Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance.Current status and future directions in the management of chronic hepatitis C.Treating hepatitis C infection by targeting the host.Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphismsAnti-HCV drugs in the pipeline.Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular CarcinomaInvestigational drugs for hepatitis C.HCV drug discovery aimed at viral eradication.Targeting mitochondrial function for the treatment of acute spinal cord injury.Antiviral therapy for hepatitis C virus: beyond the standard of care.Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress.Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.Update on the Development of Anti-Viral Agents Against Hepatitis C.Cyclophilin inhibitors as a novel HCV therapy.Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction.Dissociation kinetics of a binary complex in solution by protein displacement.In-cell NMR: from metabolites to macromolecules.Characterization of the anti-hepatitis C virus activity of new non-peptidic small-molecule cyclophilin inhibitors with a potential for broad anti-Flaviviridae activity.
P2860
Q23011530-3CD89763-9DD2-440F-9EC6-3126543502D0Q26771251-300AB489-F015-437F-85FF-5C48040577E9Q26828727-A4C0F7A9-7211-41C4-BF33-38405D514FD4Q27489053-77121B60-EEFE-404B-B43C-68A9DC2AB0BEQ27490545-13BB2510-0C14-4142-91A6-24A6488E88F8Q28541048-6EE020C5-AFEE-466E-BC26-6081F52C0EB9Q28743482-E2F6A469-44D6-4A38-BA40-56D03CFE85C3Q28748683-EC32401C-AA57-495D-BD08-AEC5C723BECEQ30829164-8ADC527F-FC9E-4479-AF2B-CD70A5D3F204Q31132161-BF7984DA-9529-482E-BCA8-07BC7F350B55Q34309568-8957C481-076C-4BCF-9B05-9D8F7DCE92FCQ34315915-A8AE6B95-9BDA-4791-A064-885CEADB2B93Q34329744-B49BBC54-2E8B-4A68-B0A2-F27611EEE615Q34409020-4C739157-76B6-4EB1-8694-A780FC4BFF57Q34530512-2C221523-D2CC-43EF-BDCD-0C001185F6EDQ35026553-641F637A-26F3-4ADF-8A4E-FB2A45A0A46DQ35063336-8961657C-A534-4ABE-9BF6-CC8E3BD83F51Q35105567-F991D370-871A-4217-A74C-731F86CCB1FDQ35650866-E485DD52-5F4F-4785-A3E7-0C40E08BBF95Q35887719-7276571B-3444-4E59-99DD-6F0EC2FA5CBCQ35992555-17F87DB7-3F08-4259-98B3-1A99DB5A79B4Q36993953-4BB08AC0-143F-4314-BC7B-0342B06F51EFQ37177740-7220BDED-88EB-4BCC-87B5-DC48140CE710Q37297666-37244A42-5CB1-473E-BA07-0064E062784DQ37650377-C82A4024-6BB3-42E4-883A-BB1315D64EDBQ37664059-1E9BF477-2A6A-48B5-9748-CECCBDBA6C9BQ37848238-A164A9C7-95C8-47E8-BE12-9E5BBBF7A6DDQ37945201-E15FE193-D1A6-401C-8C9A-072BBCDA29F6Q38174062-5454DA27-0974-4534-A8D1-D678DA27178BQ38283239-1D8FC97C-9C48-4706-8A00-B7DAE0E23960Q38584271-3CDCED14-3402-485B-A246-95A4C90D3402Q38615621-53898CCC-63B3-4075-AB94-3BE61338136DQ38990715-45F26E34-EC9E-4DED-8A18-DD3762FEAE6DQ39579921-B91792D1-8414-4B91-88DA-153A86BB73D0Q39747173-F3A7AEAB-428B-4B11-A7DB-B63A7E04AD24Q40998392-A17B227D-936B-459F-9FEA-3F04883A737AQ43047940-DD7E274E-ADF1-4DDC-A555-C029EE243F3EQ44698570-3208B258-0B87-401A-836D-42BB659C7110Q48245958-1D69B0C6-EF56-4FF9-96A3-A4B0D2235276Q54212189-CC3692B8-DC6C-4B35-B0A1-98638AC2E182
P2860
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@ast
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@en
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@nl
type
label
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@ast
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@en
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@nl
altLabel
Debio 025, a Cyclophilin Bindi ...... py for HCV (STAT-C) Inhibitors
@en
prefLabel
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@ast
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@en
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@nl
P2860
P50
P3181
P356
P1476
Debio 025, a cyclophilin bindi ...... py for HCV (STAT-C) inhibitors
@en
P2093
Grégoire Vuagniaux
Jean-Maurice Dumont
P2860
P304
P3181
P356
10.1128/AAC.00939-08
P407
P577
2009-03-01T00:00:00Z